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Edited by Jesus AvilaAbstract Recent reports have shown that prions, the causative
agent of transmissible spongiform encephalopathies, accumulate
in the skeletal muscle of diseased animals and man. In an at-
tempt to characterise in this tissue the prion protein (PrPC),
whose conformational rearrangement governs the generation of
prions, we have analysed the protein in primary cultured murine
myocytes and in diﬀerent skeletal muscle types. Our results indi-
cate that the expression and cellular processing of PrPC change
during myogenesis, and in muscle ﬁbres with diﬀerent contractile
properties. These ﬁndings imply a potential role for PrPC in the
skeletal muscle physiology, but may also explain the diﬀerent
capability of muscles to sustain prion replication.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Prions are novel infectious particles responsible for the onset
and propagation of neurodegenerative disorders of animals
and man, known as transmissible spongiform encephalopa-
thies (TSE), or prion diseases. Prions lack detectable amounts
of nucleic acids, and consist mainly of a protein, PrPSc, having
the same primary structure and post-translational modiﬁca-
tions of the cellular prion protein, PrPC, a constitutive sialogly-
coprotein expressed particularly in the central nervous system
(CNS). According to the ‘‘protein only’’ hypothesis, PrPSc
arises only from conformational changes of PrPC [1].
TSEs develop on genetic, sporadic or infectious grounds,
and are typically marked by neuronal death and astroglial pro-
liferation. It has been shown, however, that prions can also
replicate and accumulate in skeletal muscles [2–6], thereby
increasing the concern about prion transmissibility following
ingestion of TSE-tainted meat. On the other hand, other data
have linked neuronal degeneration with skeletal muscle altera-
tions. The P102L mutation of the PrP gene (PRNP), for exam-Abbreviations: CJD, Creutzfeldt–Jacob disease; CNS, central nervous
system; DIV, days in vitro; DMEM, Dulbecco-modiﬁed Eagle’s
medium; GPI, glycosylphosphatidylinositol; IB, inclusion-body;
Mab, monoclonal antibody; MHC, myosin heavy chain; Pab, poly-
clonal antibody; PBS, phosphate buﬀered saline; PIPLC, phosphati-
dylinositol-speciﬁc phospholipase C; PNGase F, peptide N-glycosidase
F; PrPC, cellular prion protein; PrPSc, scrapie prion protein; rPrP,
recombinant PrP; SDS, sodium dodecyl-sulphate; TSE, transmissible
spongiform encephalopathies
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Scheinker familial syndrome, manifests with severe peripheral
neuropathy and myopathic features, including amiotrophy and
hind-limb paralysis [7,8]. Fibre grouping and occasional
degenerating ﬁbres have been observed in the skeletal muscle
of transgenic mice expressing the corresponding PrP mutant
[9], while a progressive primary myopathy develops in those
bearing a transgene coding for the murine homologue of a hu-
man insertional mutation (PG14) associated with inherited
Creutzfeldt–Jacob disease (CJD) [10]. Under certain circum-
stances, also native PrPC may play some role in muscle degen-
eration. This was observed in mice expressing high copy
numbers of wild-type PrP transgenes [11], and in some human
muscle diseases (e.g. sporadic inclusion-body (IB) myositis,
and hereditary IB myopathy) with PrPC accumulation in mus-
cle ﬁbres [12–14]. Importantly, IB myositis can also favour the
deposition of prions in the skeletal muscle, as was reported for
a case of sporadic CJD [15].
Regarding the PrPC behaviour in myocytes, studies on the
still ill deﬁned PrPC physiology have concentrated mainly on
the neuronal, or astroglial, isoform. To our knowledge, the
only study of muscle PrPC at the cell level is that using the
C2C12 cell line, showing that PrPC expression increases as
myocytes diﬀerentiate [16]. Consistent with the hypothesised
function of PrPC in cell survival [17], this study has also re-
ported that PrPC upregulation is accompanied by a parallel in-
crease of superoxide dismutase-1 activity, thus possibly
explaining why PrP-expressing myocytes are more resistant
to oxidative stress than those lacking the protein.
Using diﬀerentiating primary myocytes and whole muscles,
we report here that the expression and cellular processing of
PrPC change substantially during myogenesis. We also present
data showing that the metabolism of PrPC varies in skeletal
muscle ﬁbres with diﬀerent contractile properties.2. Materials and methods
2.1. Cell culture
Primary cultures of skeletal muscle cells were prepared from newborn
(1–3 days-old) mice (CD1, Charles River). Brieﬂy, posterior limb mus-
cles were removed and washed in phosphate buﬀered saline (PBS). The
tissue was minced and submitted to three successive treatments with
trypsin (0.1% in PBS, 30 min, 37 C). Cells were resuspended in Ham’s
F12 (Eurobio) supplemented with 10% fetal calf serum, 2 mM gluta-
mine, 100 U/ml penicillin, 100 lg/ml streptomycin (Eurobio) (prolifer-
ation medium), and seeded at a density of 3 · 105 cells (onto 13-mm
coverslips coated with collagen (0.1% in PBS)) for immunocytochemis-
try, or at a density of 1 · 106 cells (onto 35-mm collagen-coated plates)
for biochemical assays. After 48 h of incubation, the growth medium
was replaced with Dulbecco-modiﬁed Eagle’s medium (DMEM) con-
taining 2% horse serum (Eurobio), to favour myoblast diﬀerentiation.blished by Elsevier B.V. All rights reserved.
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liferation medium (with DMEM instead of Ham’s F12), and were not
allowed to reach conﬂuence to avoid spontaneous diﬀerentiation. Dif-
ferentiation was then induced as described for primary myocytes.
2.2. Antibodies
The following mono- (M) and polyclonal (P) antibodies (ab) were
used (dilutions are indicated in parenthesis). For immunoblotting:
anti-PrP monoclonal antibody (Mab) 8H4 (1/20000) (a kind gift of
Dr. M.S. Sy, Case Western University, Cleveland, OH), raised against
the human (173–185) sequence, and Mab SAF34 (kindly provided by
Dr. J. Grassi, CEA, Saclay, France), whose epitope maps within the
N-terminal octapeptide region of PrPC; anti-a tubulin Mab (1/2000)
(Sigma), anti-embryonic myosin heavy chain (MHC) Mab G6 (1/
1000), and anti-b-slow MHC Mab BA-D5 (1/3000). For immunocyto-
chemistry and immunohistochemistry: anti-PrP Mab 8H4 (1/500) and
polyclonal antibody (Pab) R10 (1/100) (Roboscreen), anti-b-slow
MHC Mab BA-D5 (1/500), and anti-fast MHC Mab BF-13 (1/500).
All anti-MHC antibodies were kindly provided by Dr. S. Schiaﬃno,
University of Padova, Italy. Secondary antibodies were from Santa
Cruz Biotechnology.
2.3. Fluorescence immunolabeling and biochemical assays
Assays for enzymic digestion with phosphatidylinositol-speciﬁc
phospholipase C (PIPLC), immunoblotting, immunocytochemistry,
ﬂuorescence microscopy, and densitometric analysis were carried out
as previously described [18,19]. For peptide N-glycosidase F (PNGase
F) digestion, tissues or cells were homogenized in 1% sodium dode-
cyl-sulphate (SDS), boiled (5 min), and diluted eightfold in de-glycosyl-
ation buﬀer (20 mM sodium phosphate (pH 8), containing 0.6% NP-40,
1% b-mercaptoethanol, 25 mM EDTA, 0.1% SDS, and 1% Triton
X-100). The equivalent of 100 lg of total proteins was then treated
(24 h, 37 C) with PNGase F (5 U) (Roche). When PNGase F was
added after PIPLC digestion, proteins in the supernatants were metha-
nol-precipitated, resuspended in 1% SDS, boiled (5 min), and processed
as above. For Western blotting of brains and of hind-limb skeletal mus-
cles from newborn and adult mice, tissues were homogenized directly in
Laemmli sample buﬀer [20] (without bromophenol blue and reducing
agents), to minimize proteolytic degradation. Total protein concentra-
tions of cell and tissue homogenates were always determined by the
BCA protein assay reagent kit (Pierce). Recombinant (r) murine PrP
(23–230) was generated following the method used for obtaining bovine
recombinant PrP (rPrP) [21]. Immunohistochemical analyses of tibialis
anterior and soleus muscles from the hind-limb of adult mice were car-
ried out on acetone-ﬁxed 10 lm-transversal cryosections.
2.4. Real time RT-PCR analysis
Total RNAs from primary muscle cell cultures were extracted, at the
indicated times, by SV Total RNA Isolation System (Promega),
according to the manufacturer’s instructions. RNA quality and quan-
tity were assessed by measuring the A260/A280 ratio and by analysis on
ethidium bromide-stained 1% agar gels. Reverse transcription was per-
formed using 5 lg of total RNA, an oligo-dT primer, and Super-
Script II RT (Invitrogen). cDNA products were treated with
DNAse-free RNAse H (Life Technologies) before PCR analysis. Real
time RT-PCR was carried out according to Karsai et al. [22], using the
SYBR Green I method (Applied Biosystem) and a Rotor-Gene cycler
(Corbett Research). In preliminary experiments, serial dilutions of the
cDNA templates were used to establish the optimal amount required
for ampliﬁcation. Kinetic conditions were as follows: a preliminary
hot step (9 min, 95 C) was followed by denaturation (30 s, 95 C),
annealing (30 s, 60 C, for all used primers), and extension (30 s,
72 C). Data were analysed using the Rotor-Gene Analysis Software
(Corbett Research) and the mathematical model described by Pfaﬄ
[23]. Relative mRNA levels were calculated with respect to those ob-
served at 48 h of culture, and normalised to those of the housekeeping
RPS-16 gene (encoding the S16 ribosomal protein). Used primers were:
mouse PrP forward (FWD): 5 0-ATGGCGAACCTTGGCTACTG-30,
reverse (REV): 5 0-CCTGAGGTGGGTAACGGTTG-3 0 (amplicon
length, 157 bp); mouse MyoD FWD: 5 0-GCCGCCTGAGCAAAGT-
GAATG-3 0, REV: 5 0-CAGCGGTCCAGGTGCGTAGAAG-3 0
(amplicon length, 191 bp); mouse S16 FWD: 5 0-GCAGTACAAGT-
TACTGGAGCC-3 0, REV: 5 0-CGGTAGGATTTCTGGTATCG-3 0
(amplicon length, 297 bp).3. Results
Because of the little attention thus far devoted to the physi-
ology of muscle PrPC, our study addressed the issue of the
properties of this isoform either in primary myocytes, or in dif-
ferent skeletal muscles.
3.1. PrPC amounts and processing change during in vitro
myogenesis
Firstly, by immunoassay we followed if and how the expres-
sion of PrPC varied at diﬀerent in vitro maturation stages of iso-
lated myocytes. To this end, we employed skeletal muscle
primary cultures derived from the hind-limb of newborn mice.
Under conditions of low serum and high cell density, immature
cells (myoblasts) normally diﬀerentiate and fuse into mature,
self-contracting polynucleated myotubes within 6 days in vitro
(DIV) from their isolation [24].
As shown in the Western blot of cells at diﬀerent DIV cultur-
ing (lanes 1, 3, and 5 of Fig. 1A), and in the blot densitometric
analysis of one (out of 10) such experiment (Fig. 1B), PrPC
expression clearly increases with the progression of the diﬀeren-
tiation process. It is good to mention, however, that there was
some variability in the detected maximal increase of PrPC (be-
tween 5- and 10-fold), possibly because the cell content of the
protein changes substantially from one culture to another with-
in 2 DIV, i.e. in that same time period when the rise of PrPC
expression is likely to be triggered. Fig. 1A also shows that, of
all glycoforms typical of PrPC [14], the (mature) di-glycosylated
one (of approximately 34 kDa mass, black arrowhead) is that
which becomes prevalent in fully diﬀerentiated cells (at 6 DIV).
A further insight in the processing of PrPC during myogen-
esis is given by the pattern arising from treating cells with the
de-glycosylating PNGase F enzyme. Indeed, sugar removal
highlights that, at all stage, cells harbour two PrPC truncated
forms (migrating with mass around 20 and 18 kDa) (Fig. 1A,
even lanes). As the fragments were labelled by antibody to
the C-terminal (Mab 8H4) (Fig. 1A), but not the N-terminal
(Mab SAF34, not shown), epitope of PrPC, this result suggests
that both truncated forms originate from the N-terminal cleav-
age of the protein [14,25,26]. To note that, at 2 DIV, PrPC
fragments are more abundant than the full-length isoform
(white arrowhead), and migrate with a slightly higher mobility
than those detected at later stages.
We routinely controlled the diﬀerentiation progress of each
used primary culture by both morphological observations
(see, for example, Fig. 2A), and by following the expression
of in vitro late diﬀerentiation markers, such as troponin T
(not shown) and embryonic MHC. As shown (Fig. 1C), the lat-
ter rightfully becomes abundant in 6 DIV-cells. Moreover, gi-
ven that immortalised C2C12 murine myocytes, subjected to
identical diﬀerentiating protocols, maturate with increasing
PrPC contents (not shown; see also [16]), we could discard
the possibility that the time-dependent PrPC increase in pri-
mary myocytes pertains to contaminating non-muscle cells.
Of importance, the in vitro maturation pattern of PrPC
replicates in vivo. This is evident from the immunoblotting of
skeletal muscles reported in Fig. 1D, showing that, compared
to newborns, adult mice display a higher total amount of
mature PrPC (lanes 1 and 3), and the N-truncated fragments
are relatively less abundant and migrate with a slightly higher
apparent mass (lanes 2 and 4). Clearly, being present also in
the brain homogenate of adult mice (Fig. 1D, lanes 5–6), these
Fig. 1. Both the expression and maturation of PrPC increase in in vitro diﬀerentiating skeletal myocytes and in developing skeletal muscles. (A)
Myoblasts from newborn mice hind-limb skeletal muscles were grown for the indicated days in vitro (DIV), under conditions that stimulate the
complete diﬀerentiation into mature myotubes. Cell lysates, treated (+) or not () with the sugar-removing enzyme PNGase F (5 U, 24 h, 37 C),
were subjected to 12% SDS–PAGE, after which proteins were electroblotted onto nitrocellulose membranes, and labelled with Mab 8H4 to PrP.
Arrowheads indicate the diﬀerent PrPC glycoforms, i.e. un-glycosylated (white), mono-glycosylated (grey) and di-glycosylated (black). Clearly, not
only PrPC becomes more abundant with time, and expresses preferentially the di-glycosylated form, but the enzymic treatment also discloses the
presence of PrPC proteolytic fragments. Murine rPrP (23–231) was run as reference (far right lane), while molecular mass standards are reported on
the left. (B) Bar diagram reporting the relative intensity (determined by densitometric analysis) of total PrP-immunoreactive bands found in PNGase
F-untreated cells grown for the indicated times. Band intensities were ﬁrst normalised to total loaded protein amounts, and then expressed relative to
those at 2 DIV. Shown data (means ± SD), from an experiment (run in triplicate) representative of ten independent experiments, outline a more than
ﬁve-fold increase of PrPC expression at 6 DIV. (C) PNGase F-untreated samples used in (A) were immunoblotted with Mab G6 to embryonic MHC.
Being a marker of the in vitro muscle diﬀerentiation late stages, this protein rightfully becomes abundant at 6 DIV. Other experimental details were as
reported in (A). (D) The Western blotting of homogenates of hind-limb skeletal muscles from newborn (lanes 1–2) and adult (lanes 3–4) mice, treated
(+) or not () with PNGase F, indicates that the increase of PrPC expression and maturation observed in vitro (see above) occurs also in vivo. Lanes
5 and 6, loaded with one quarter the protein amount used for muscle analyses, show the comparative immunoblot of murine adult brain homogenate,
treated (+) or not () with PNGase F. Other experimental details were as reported in (A). (E) Quantiﬁcation of PrP mRNA during muscle in vitro
diﬀerentiation. mRNA levels were evaluated by real time RT-PCR, after extraction of total mRNA from primary myocytes cultured under
diﬀerentiating conditions for the indicated DIV. Relative mRNA levels of PrPC (light grey), and MyoD (an early marker of muscle in vitro
diﬀerentiation) (dark grey), were normalised to those of the housekeeping RPS-16 gene. Although the sensitivity of the RT-PCR assay detects PrP
mRNA already at 1 DIV, reported values are expressed relative to those at 2 DIV to facilitate comparison with data of panel (B). Shown data is
representative of one out of three independent experiments, and indicates that the augment of PrPC during the maturation of myocytes (panels (A)
and (B)) is determined, at least in part, by increased Prnp transcriptions and/or higher RNA stabilities.
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to be determined whether they play some role in the develop-
ment of the previously observed myopathic traits.
Real-time RT-PCR was then used to understand whether
the observed ampliﬁcation of PrPC expression was consequent
to increased Prnp transcription rates. Indeed, as shown in
Fig. 1E (light grey bars), diﬀerentiation is accompanied by
increasing levels of PrP mRNA, although to a lesser extent
than what found for the translated protein (cf. Fig. 1B). This
result suggests that a rise in Prnp transcription, and/or in-
creased RNA stability, governs, at least in part, PrPC ampliﬁ-
cation during muscle development. Conversely, the mRNA of
MyoD ﬁrst increases, then decreases with time (Fig. 1E, dark
grey bars), in keeping with the notion that MyoD marks the
early diﬀerentiation stage of myocytes [27].3.2. Cellular distribution of muscle PrPC
The distribution of PrPC in primary myocytes was examined
by immunolabelling (at 4 C) intact cells with anti-PrP Mab
8H4. In agreement with the observed biochemical features,
the signal was absent, or weak, in immature cells and/or in
other contaminating cell types (which, however, can be recog-
nised as the small, mononucleated elements marked by yellow
arrowheads in Fig. 2A), but not in polynucleated myotubes (at
6 DIV) that showed an intense surface ﬂuorescence (Fig. 2A).
Being the protein normally exposed on the cell surface through
the glycosylphosphatidylinositol (GPI) moiety, the latter result
is in agreement with the known processing of PrPC [1], as was
the intracellular staining of ﬁxed and permeabilised myotubes
indicating the presence of PrPC along the secretory pathway
(not shown).
Fig. 2. Localisation of PrPC in mature primary myotubes from hind-limb skeletal muscles. (A) Fluorescence microscopy of primary myocytes at 6
DIV, treated with anti-PrP Mab 8H4 (1 h, 4 C) and then labelled (4 C) with a FITC-conjugated secondary antibody, indicates that PrPC localizes to
the cell surface of mature myotubes (left panel, green signal). Conversely, the phase-contrast microscopy (middle panel) and superposition of the left
and middle images (right panel) clearly show that PrPC is almost undetectable in (arrowhead-indicated) mononucleated cells (myoblasts that did not
diﬀerentiate, or contaminating non-muscle cells). Bar = 40 lm. (B) Immunoblots (with Mab 8H4 to PrP) of 6 DIV-primary myotubes treated (+), or
not (), with PIPLC (5 U/ml, 12 h, 37 C) that cleaves the GPI anchor. By showing that the GPI cleavage accumulates muscle PrPC in the medium
(lane 3) whilst decreasing the cell-associated form (lane 7), these data prove a correct link of the protein to the cell membrane. After PIPLC, culture
media and cell lysates were treated (+) (lanes 2, 4, 6, 8) or not () (lanes 1, 3, 5, 7) with PNGase F so as to identify all PrPC isoforms. The ﬁnding that
the two C-fragments are present in the medium (lane 4) thus indicates that also the truncated forms are bound to the cell surface through the GPI
moiety. Other details were as described in the legend to Fig. 1.
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cytes treated with PIPLC that cleaves the GPI anchor of PrPC.
This assay indicates a largely correct GPI-mediated binding of
the protein to the plasma membrane, being the enzyme capable
to decrease the cell-associated protein pool (lanes 5 and 7),
while increasing that released in the culture medium (lanes 1
and 3). Further, to identify the PIPLC-released isoforms, we
immunoblotted the proteins resulting from treatment by PNG-
ase F of the culture medium or the cell lysate. Importantly, the
ﬁnding that, along with the full length isoform, also the C-ter-
minal fragments are released in the culture medium after
PIPLC digestion (cf. lanes 2 and 4, and lanes 6 and 8), allows
to conclude that the truncated forms are surface-exposed and
GPI-anchored, and thus that they are part of the normal
metabolism of muscle cells.
3.3. PrPC amounts and glycosylation proﬁles depend on the
skeletal muscle type
Skeletal muscles can be discriminated on the basis of their
content in ‘‘fast’’ (or type 2), and ‘‘slow’’ (or type 1) ﬁbres.
The two ﬁbres express diﬀerent MHC isoforms that, responsi-
ble for the fast and slow contraction, respectively, are easily
distinguishable by immuno-based procedures [28]. We then
investigated whether PrPC expression and biochemical features
diﬀered in the fast ﬁbre-rich tibialis anterior (TA) and slow ﬁ-
bre-rich soleus of adult mice hind-limbs. Immunoblotting of
the two muscles indicated that this is the case, because PrPC
is signiﬁcantly more abundant (Fig. 3A), and reaches a higher
degree of maturation (Fig. 3B), in TA than in soleus. With re-
spect to the latter feature, the di-glycosylated form is prevalentin TA, while the un-glycosylated form predominates in soleus.
Also, PNGase F treatment reveals that in the two muscles, in
particular in TA, the C-terminal fragments are less represented
than in whole muscle homogenates, further supporting the no-
tion that the PrPC metabolism of muscle ﬁbres is highly heter-
ogeneous. Immunohistochemical investigations conﬁrmed the
ﬁbre-dependent expression of PrPC, in that an anti-PrP Pab
uniformly decorated the sarcolemma of TA fast ﬁbres (recog-
nisable by the anti-fast MHC Mab staining) (Fig. 3C, upper
panels), whereas PrPC was almost undetectable in soleus ﬁbres
reactive towards the antibody to b-slow MHC (lower panels).
Unfortunately, our diﬃculty in separating accurately murine
fore-limb fast and slow ﬁbre-rich groups did not allow to mon-
itoring the behaviour of PrPC in fore-limb ﬁbres. Interestingly,
however, analysis of the whole fore-limb muscle showed that
it predominantly expressed un-glycosylated PrPC, thus
suggesting that PrPC is processed in a speciﬁc manner in the
fore- and hind-limb, irrespective of the similar protein amount
expressed (data not shown).4. Discussion
As mentioned, a detailed characterisation of PrPC metabo-
lism in muscles is still lacking, in spite of the notion that the
protein is expressed in this tissue at appreciable levels [29–
31], and the recent evidence that prions accumulate in the skel-
etal muscle of animals and man [2–6]. By analysing PrPC in
both primary cultures, and in diﬀerent types, of skeletal mus-
cles, we have shown that, although sharing several features
Fig. 3. PrPC levels and glycosylation proﬁles diﬀer in diﬀerent skeletal muscles. (A) Left panel. The Western blotting of fast ﬁbre-rich tibialis anterior
(TA) and slow ﬁbre-rich soleus homogenates, treated (+) or not () with PNGase F, shows that PrPC is more abundant in the former muscle type. As
shown, the two muscles can also be discriminated by the diﬀerent expression levels of b-slow MHC (labelled by Mab BA-D5). Immunoblotted a-
tubulin served as an internal standard. Right panel. The densitometric analysis of three independent Western blot experiments (as that shown in the
left panel) conﬁrms that PrPC is diﬀerently expressed in the two muscles. The intensity of PrPC-immunoreactive bands was normalised to that of a-
tubulin, and reported as mean ± S.D. Other experimental details were as described in the legend to Fig. 1. (B) Densitometric analysis of TA and
soleus PrPC glycoforms (immunodetected as described in Fig. 1A). The diagram reports the relative values (with respect to total PrPC) of un-
glycosylated (x-axis) versus di-glycosylated (y-axis) PrPC. Clearly, it is TA that expresses a considerably larger content of the mature, di-glycosylated
form. Reported values are means ± S.D. (n = 3). (C) Transversal cryosections (10 lm) of TA (upper panels) and soleus (lower panels) were acetone-
ﬁxed, and co-immunolabelled with anti-PrP Pab R10 (left panels), and with either anti-fast MHC Mab BF-13 (upper right panel), or anti-b-slow
MHC Mab BA-D5 (lower right panel). With this technique, high PrPC levels are evident in anti-fast MHC Mab-reactive ﬁbres, while the protein is
almost undetectable in those stained by the anti-b-slow MHC Mab. Bar = 50 lm.
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that link the protein with muscle development and activities.
This conclusion is supported by several lines of evidence, the
ﬁrst of which regards the analysis of PrPC in in vitro diﬀerenti-
ating myocytes, an experimental paradigm that mimics the ﬁrst
stages of myogenesis. This study has shown that the cell accu-
mulation of PrPC, fully accomplished only after around 4 days
from initiating the cell culturing (Figs. 1A and B), nicely corre-
lates with the progression of the myocyte maturation (Figs. 1C
and E). Importantly, the process closely followed the rise in
Prnp transcription (Fig. 1E). However, because the increase
of mRNA was less pronounced than that of the translated pro-
tein, we reasoned that other processes could contribute to the
observed PrPC accumulation. Indeed, the prevalence, during
development, of speciﬁc glycan attachments to, and/or of N-
truncations of, PrPC (conﬁrmed by comparing hind-limb mus-
cle PrPC of adult and newborn mice (Fig. 1D)), indicates that
also the metabolism of the protein changes with time. Addition-
ally, hind-limb fast and slow ﬁbres, which express speciﬁcMHC isoforms responsible for the fast and slow muscle con-
traction, respectively, diﬀer signiﬁcantly not only for the con-
tent of PrPC but also for the processing imparted to the
protein (Fig. 3). This result further supports interplay between
the metabolism of PrPC and that of the skeletal muscle, if not of
each ﬁbre type. Interestingly, the ﬁnding that myocytes with no,
or little, PrPC are more susceptible to oxidative stress than cells
fully expressing the protein, has led to suggesting that PrPC
functions in counteracting oxidative challenge [16]. This no-
tion, which is in line with the proposition that embryonic
CNS responds with increasing PrPC when switching from
anaerobic to mitochondria-based aerobic metabolism [31],
seems, however, not readily applicable to the diﬀerent PrPC
proﬁles of fast and slow ﬁbres (Fig. 3), where a lower PrPC con-
tent is typical of slow ﬁbres that, with more mitochondria than
the glycolitic fast ones, are likely to face, hence handle, a larger
production of reactive oxygen species [28]. In concluding, the
shown behaviour of muscle PrPC allows to reiterate the impor-
tance of the protein in muscle physiology, as also suggested by
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Yet, because also neural PrPC increases during embryogenesis
and in the ﬁrst 42 days of the postnatal life [31], it is tempting
to consider Prnp activation as a common mechanism of all
developing tissues.
Another interesting aspect of our study may relate to the
pathological implication of PrPC, e.g. to the ﬁnding that some
muscles are more apt than others to accumulate prions.
According to Bosque and coworkers [2], for example, prions
accumulate in the hind-, not in the fore-, limb of experimen-
tally infected animals, but even when prions are spread in all
skeletal muscles, infectivity titres markedly diﬀer from one
muscle to the other, with the fore-limb showing the least value
[5]. It has been proposed that such a tropism may depend on
the expression of cellular auxiliary factor(s) [2]; however, it is
also possible that both the expression level, and the processing,
of PrPC favour the formation of muscle prions. Undoubtedly,
the report that prions accumulate in muscles when inﬂamma-
tion (or inﬂammation-dependent processes) induces PrPC over-
expression [15] ﬁts well with a PrPC abundancy-prion
replication linkage. Yet, our observation that similar PrPC
amounts are nonetheless processed in a speciﬁc way by hind-
and fore-limb muscles discloses the possibility that the protein
metabolism may also come into play in muscle prion replica-
tion, thereby explaining why fore-limbs sustain this process
less eﬃciently [2,5].
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